AustraliaHealth

Mesoblast (ASX:MSB) has treated 300 patients in a key clinical trial to validate a new low back pain therapy.

Pacific Edge (ASX:PEB) announced that its Asia Pacific business is advancing towards profitability on a direct-cost basis.

Ryman Healthcare (ASX:RYM) reported 325 sales of retirement living occupation right agreements for the quarter ended June 30.

OncoSil Medical (ASX:OSL) completed three manufacturing validation cycles to establish a local production capability for over 50 device doses.

Regis Healthcare (ASX:REG) announced that CFO Rick Rostolis will retire from his position effective Aug. 31.

Clinuvel (ASX:CUV) secured regulatory approval from Health Canada to market its 16mg SCENESSE drug for adult patients with erythropoietic protoporphyria.

Mesoblast (ASX:MSB) reported a full-year net revenue of US$115 million following increased sales of its approved cellular medicine.

Sigma Healthcare (ASX:SIG) announced that co-founders Sam and Jack Gance may sell up to 20% of their combined $7.7 billion stake.

ReNerve (ASX:RNV) has secured a convertible note funding facility of up to $5 million to support its commercialisation strategy.

ResMed (ASX:RMD) signed an agreement to sell its MatrixCare software business to private equity firm Frazier Healthcare Partners.

Imugene (ASX:IMU) secured firm commitments to raise $11.1 million via a share placement to fund its cancer clinical trials.

Argent BioPharma (ASX:RGT) executed a binding transaction framework for the exclusive global licensing of its epilepsy asset CannEpil.